M
Matteo Puntoni
Researcher at University of Genoa
Publications - 148
Citations - 5145
Matteo Puntoni is an academic researcher from University of Genoa. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 31, co-authored 132 publications receiving 4358 citations. Previous affiliations of Matteo Puntoni include Westmead Hospital & European Association of Nuclear Medicine.
Papers
More filters
Journal ArticleDOI
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Andrea Decensi,Matteo Puntoni,Pamela J. Goodwin,Massimiliano Cazzaniga,Alessandra Gennari,Bernardo Bonanni,Sara Gandini +6 more
TL;DR: A comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients found that the inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer.
Journal ArticleDOI
Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial
Francesco Boccardo,Alessandra Rubagotti,Matteo Puntoni,Pamela Guglielmini,Domenico Amoroso,Angela Fini,Giuseppe Paladini,Mario Mesiti,Domenico Romeo,Michela Rinaldini,Simona Scali,M. Porpiglia,Chiara Benedetto,Nunzio Restuccia,Franco Buzzi,Roberto Franchi,Bruno Massidda,Vito Distante,Dino Amadori,P. Sismondi +19 more
TL;DR: Switching to anastrozole after the first 2 to 3 years of treatment is well tolerated and significantly improves event-free and recurrence-free survival in postmenopausal patients with early breast cancer.
Journal ArticleDOI
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-Analysis taking into account Biases and Confounders
Sara Gandini,Matteo Puntoni,Brandy M. Heckman-Stoddard,Barbara K. Dunn,Leslie G. Ford,Andrea Decensi,Eva Szabo +6 more
TL;DR: The results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally.
Journal ArticleDOI
HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
Alessandra Gennari,Maria Pia Sormani,Paolo Pronzato,Matteo Puntoni,Mariantonietta Colozza,Ulrich Pfeffer,Paolo Bruzzi +6 more
TL;DR: The added benefits of adjuvant chemotherapy with anthracyclines appear to be confined to women who have HER2 overexpressed or amplified breast tumors.
Journal ArticleDOI
Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial
Bernardo Bonanni,Matteo Puntoni,Massimiliano Cazzaniga,Giancarlo Pruneri,Davide Serrano,Aliana Guerrieri-Gonzaga,Alessandra Gennari,Maria Stella Trabacca,Viviana Galimberti,Paolo Veronesi,Harriet Johansson,Valentina Aristarco,Fabio Bassi,Alberto Luini,Matteo Lazzeroni,Clara Varricchio,Giuseppe Viale,Paolo Bruzzi,Andrea Decensi +18 more
TL;DR: Metformin before surgery did not significantly affect Ki-67 overall, but showed significantly different effects according to insulin resistance, particularly in luminal B tumors.